Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Novartis Sees CML Med Scemblix as Growth Driver over Next Decade, 1st Line Use Holds Key
June 8, 2022
-
REGULATORY Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out
June 8, 2022
-
REGULATORY Pharmacist LDP Candidate Eager for National Debate on Drug Pricing
June 7, 2022
-
REGULATORY Public-Private Confab Set for June 14, Talks on Data Utilization Expected
June 7, 2022
-
REGULATORY Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi
June 6, 2022
-
BUSINESS Gilead Japan Eyes High-Single-Digit Annual Growth with Oncology as Third Biz Pillar
June 3, 2022
-
COMMENTARY New Zero Premium Rule Applied to 6 Drugs Since April Rollout, Is It Incentivizing Cost Disclosure?
June 2, 2022
-
BUSINESS Shashank Deshpande to Take Reins at Nippon Boehringer Ingelheim
June 2, 2022
-
REGULATORY Honebuto Draft Makes No Mention of Off-Year Re-Pricing or Buffer Zone, Calls for Stronger Drug Discovery Capabilities
June 1, 2022
-
BUSINESS Takeda to Transfer Spikevax Authorization to Moderna in Japan, 3-Way Purchase Deal to End
June 1, 2022
-
ACADEMIA NCGM, IQVIA Pair Up to Unravel “Long COVID” by Building Large-Scale Registry
May 31, 2022
-
REGULATORY Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
May 31, 2022
-
BUSINESS Japan Drug Majors Expand Global Oncology Sales in FY2021
May 30, 2022
-
BUSINESS Moderna Eyes Bivalent Booster Rollout This Fall via Emergency Approval Path in Japan: CMO
May 30, 2022
-
BUSINESS AstraZeneca Tops Foreign Pharma Ranking in 2021, Pfizer Sales Undisclosed: Jiho
May 27, 2022
-
REGULATORY Japan Approves Additional Indications, Dosages for Rinvoq, Adcetris, Rozex, and More
May 27, 2022
-
BUSINESS Top 4 Wholesalers Log 62% Rise in Operating Profit in FY2021 on Rebound in Doctor Visits
May 27, 2022
-
BUSINESS Sandoz Japan on Hunt for Biosimilar In-Licensing, Sales Tie-Ups after Avastin Deal
May 26, 2022
-
BUSINESS Japan Pharma Market Up 3.3% in FY2021, Opdivo Rises to No.1: IQVIA
May 26, 2022
-
REGULATORY MOF Panel Nudges Full Annual Drug Re-Pricing, Phase-Out for 2% Buffer Zone
May 26, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…